Overview

A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).
Phase:
PHASE2
Details
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd